Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator-initiated Trial to Evaluate the Efficacy and Safety of Anti-CD19 Universal CAR-T Cells in the Treatment of Relapsed/Refractory(r/r) CD19+ B-cell Acute Lymphoblastic Leukemia(B-ALL)

NCT05639179 is registered in ClinicalTrials.gov with 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China as lead sponsor.

NCT NCT05639179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05639179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator-initiated Trial to Evaluate the Efficacy and Safety of Anti-CD19 Universal CAR-T Cells in the Treatment of Relapsed/Refractory(r/r) CD19+ B-cell Acute Lymphoblastic Leukemia(B-ALL)
Lead sponsor
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 5, 2022
Completion date
December 31, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-all, b-cell acute lymphoblastic leukemia